- Home
- BMEA vs SPCB Comparison
BMEA vs SPCB Comparison
Compare BMEA & SPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- SPCB
- Stock Information
- Founded
- BMEA 2017
- SPCB 1988
- Country
- BMEA United States
- SPCB Israel
- Employees
- BMEA N/A
- SPCB N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- SPCB Semiconductors
- Sector
- BMEA Health Care
- SPCB Technology
- Exchange
- BMEA Nasdaq
- SPCB Nasdaq
- Market Cap
- BMEA 65.8M
- SPCB 53.3M
- IPO Year
- BMEA 2021
- SPCB N/A
- Fundamental
- Price
- BMEA $1.81
- SPCB $10.42
- Analyst Decision
- BMEA Strong Buy
- SPCB Strong Buy
- Analyst Count
- BMEA 10
- SPCB 1
- Target Price
- BMEA $22.30
- SPCB $18.00
- AVG Volume (30 Days)
- BMEA 5.2M
- SPCB 213.2K
- Earning Date
- BMEA 07-30-2025
- SPCB 08-14-2025
- Dividend Yield
- BMEA N/A
- SPCB N/A
- EPS Growth
- BMEA N/A
- SPCB N/A
- EPS
- BMEA N/A
- SPCB 1.89
- Revenue
- BMEA N/A
- SPCB $27,831,000.00
- Revenue This Year
- BMEA N/A
- SPCB $2.73
- Revenue Next Year
- BMEA N/A
- SPCB $22.87
- P/E Ratio
- BMEA N/A
- SPCB $5.51
- Revenue Growth
- BMEA N/A
- SPCB 2.90
- 52 Week Low
- BMEA $1.29
- SPCB $2.55
- 52 Week High
- BMEA $13.07
- SPCB $18.95
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- SPCB 56.38
- Support Level
- BMEA $2.24
- SPCB $9.46
- Resistance Level
- BMEA $3.08
- SPCB $11.18
- Average True Range (ATR)
- BMEA 0.40
- SPCB 1.01
- MACD
- BMEA -0.03
- SPCB -0.15
- Stochastic Oscillator
- BMEA 25.07
- SPCB 45.13
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About SPCB SuperCom Ltd. (Israel)
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.